{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T06:55:24Z","timestamp":1791096924157,"version":"4.1.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2013,11,30]],"date-time":"2013-11-30T00:00:00Z","timestamp":1385769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,11,30]],"date-time":"2013-11-30T00:00:00Z","timestamp":1385769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s40265-013-0153-9","type":"journal-article","created":{"date-parts":[[2013,11,29]],"date-time":"2013-11-29T07:28:45Z","timestamp":1385710125000},"page":"2093-2106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Simeprevir: First Global Approval"],"prefix":"10.1007","volume":"73","author":[{"given":"Asha","family":"Vaidya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,30]]},"reference":[{"key":"153_CR1","unstructured":"World Health Organization. Hepatitis C: Fact sheet N\u00b0164. http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/. Accessed 14 Oct 2013."},{"key":"153_CR2","unstructured":"World Health Organization. Hepatitis C. http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/. Accessed 7 Nov 2013."},{"issue":"5","key":"153_CR3","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1053\/j.gastro.2008.07.023","volume":"135","author":"Y Liang","year":"2008","unstructured":"Liang Y, Ishida H, Lenz O, et al. Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors. Gastroenterology. 2008;135(5):1710\u20138.e2.","journal-title":"Gastroenterology"},{"key":"153_CR4","unstructured":"Centers for Disease Control and Prevention. Hepatitis C information for health professionals. http:\/\/www.cdc.gov\/hepatitis\/hcv\/hcvfaq.htm#-. Accessed 7 Nov 2013."},{"issue":"5","key":"153_CR5","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2165\/11208370-000000000-00000","volume":"72","author":"C Perry","year":"2012","unstructured":"Perry C. Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C. Drugs. 2012;72(5):619\u201341.","journal-title":"Drugs."},{"issue":"18","key":"153_CR6","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.2165\/11209560-000000000-00000","volume":"72","author":"K Garnock-Jones","year":"2012","unstructured":"Garnock-Jones K. Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection. Drugs. 2012;72(18):2431\u201356.","journal-title":"Drugs."},{"issue":"14","key":"153_CR7","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.2165\/11635560-000000000-00000","volume":"72","author":"PJ Pockros","year":"2012","unstructured":"Pockros PJ. Interferon-free hepatitis C therapy: how close are we? Drugs. 2012;72(14):1825\u201331.","journal-title":"Drugs."},{"issue":"4","key":"153_CR8","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1128\/AAC.01058-08","volume":"53","author":"T-I Lin","year":"2009","unstructured":"Lin T-I, Lenz O, Fanning G, et al. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother. 2009;53(4):1377\u201385.","journal-title":"Antimicrob Agents Chemother."},{"issue":"12","key":"153_CR9","doi-asserted-by":"publisher","first-page":"5288","DOI":"10.1128\/AAC.00777-10","volume":"54","author":"A Bae","year":"2010","unstructured":"Bae A, Sun S-C, Qi X, et al. Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors. Antimicrob Agents Chemother. 2010;54(12):5288\u201397.","journal-title":"Antimicrob Agents Chemother."},{"issue":"2","key":"153_CR10","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/apt.12350","volume":"38","author":"K Rutter","year":"2013","unstructured":"Rutter K, Hofer H, Beinhardt S, et al. Durability of SVR in chronic hepatitis C patients treated with peginterferon-alpha2a\/ribavirin in combination with a direct-acting anti-viral. Aliment Pharmacol Ther. 2013;38(2):118\u201323.","journal-title":"Aliment Pharmacol Ther."},{"key":"153_CR11","unstructured":"Medivir AB. Simeprevir has been approved in Japan for the treatment of genotype 1 chronic hepatitis C infection. 2013. http:\/\/www.medivir.com. Accessed 7 Nov 2013."},{"key":"153_CR12","unstructured":"Medivir AB. The regulatory process in Japan for simeprevir. 2013. http:\/\/www.medivir.com. Accessed 7 Nov 2013."},{"key":"153_CR13","unstructured":"Medivir AB. Regulatory Application has now been filed for simeprevir (TMC435) in Japan for the treatment of genotype 1 hepatitis C patients. 2013. http:\/\/www.medivir.com. Accessed 7 Nov 2013."},{"key":"153_CR14","unstructured":"Medivir. Simeprevir has been approved in Canada as a new treatment for hepatitis C. http:\/\/www.medivir.se\/v5\/en\/uptodate\/pressrelease.cfm"},{"key":"153_CR15","unstructured":"Janssen Research Development LLC. U.S. FDA grants priority review to simeprevir (TMC435) for combination treatment of genotype 1 chronic hepatitis C. 2013. http:\/\/www.janssenrnd.com. Accessed 7 Nov 2013."},{"key":"153_CR16","unstructured":"Janssen Research Development LLC. Janssen submits New Drug Application to U.S. FDA for simeprevir (TMC435) for combination treatment of adult patients with genotype 1 chronic hepatitis C. 2013. http:\/\/www.janssenrnd.com. Accessed 7 Nov 2013."},{"key":"153_CR17","unstructured":"Medivir AB. Medivir: New Drug Application has been filed with FDA for Simeprevir (TMC435) for combination treatment of adult patients with genotype 1 chronic hepatitis C. 2013. http:\/\/www.medivir.com. Accessed 7 Nov 2013."},{"key":"153_CR18","unstructured":"Medivir. TMC435 has received fast track designation from the FDA and TMC435 will be studied in combination with Pharmasset\u2019s PSI-7977 for HCV genotype-1. 2011. http:\/\/www.medivir.com. Accessed 7 Nov 2013."},{"key":"153_CR19","unstructured":"Medivir AB. Marketing Authorization Application for simeprevir to the EMA for the treatment of patients with genotype 1 and genotype 4 hepatitis C is now filed. 2013. http:\/\/www.medivir.se. Accessed 7 Nov 2013."},{"key":"153_CR20","unstructured":"Janssen Therapeutics EMEA. Janssen creates new division to launch TMC435 and help conquer hepatitis C in EMEA. 2012. http:\/\/emea.janssentherapeutics.com. Accessed 7 Nov 2013."},{"key":"153_CR21","unstructured":"Medivir. Medivir: Tibotec files application to start a phase I clinical trial for HCV inhibitor. 2006. http:\/\/www.medivir.se. Accessed 7 Nov 2013."},{"key":"153_CR22","unstructured":"Medivir. Tibotec files application to start a phase I clinical trial for HCV inhibitor. 2006. http:\/\/www.medivir.se. Accessed 7 Nov 2013."},{"key":"153_CR23","unstructured":"Medivir AB. Medivir AB enters into license and research collaboration agreement on hepatitis C. 2004. http:\/\/www.medivir.se\/OuterFrameEng.asp. Accessed 7 Nov 2013."},{"key":"153_CR24","unstructured":"Medivir AB. Medivir announces TMC435 in an expanded clinical collaboration. 2012. http:\/\/www.medivir.com. Accessed 7 Nov 2013."},{"key":"153_CR25","unstructured":"Medivir AB. An all-oral combination phase II study of simeprevir and samatasvir (IDX719) for the treatment of hepatitis C virus infection initiated. 2013. http:\/\/www.medivir.com. Accessed 7 Nov 2013."},{"key":"153_CR26","unstructured":"Idenix Pharmaceuticals Inc. Idenix Pharmaceuticals announces collaboration with Janssen to initiate phase II all-oral combination studies including IDX719, simeprevir (TMC435) and TMC647055 for the treatment of hepatitis C virus (HCV). 2013. http:\/\/www.idenix.com. Accessed 7 Nov 2013."},{"key":"153_CR27","unstructured":"Janssen Pharmaceuticals I. Janssen announces collaboration with Vertex on phase 2 study to investigate an all-oral regimen of simeprevir (TMC435) and VX-135 for treatment of hepatitis C. 2012. http:\/\/www.janssenrnd.com. Accessed 7 Nov 2013."},{"key":"153_CR28","unstructured":"Vertex Pharmaceuticals I. Vertex announces collaboration with Janssen to initiate phase 2 all-oral study of VX-135 and simeprevir (TMC435) for the treatment of hepatitis C. Media Release. 2012."},{"key":"153_CR29","unstructured":"Bristol-Myers Squibb Company. Bristol-Myers Squibb enters clinical collaboration agreement with Tibotec Pharmaceuticals for phase II combination study in patients chronically infected with hepatitis C. 2011. http:\/\/www.bms.com. Accessed 7 Nov 2013."},{"key":"153_CR30","unstructured":"Pepscan Therapeutics. Pepscan therapeutics achieves milestones in research collaboration with Janssen R and D Ireland. 2012. http:\/\/www.pepscan.com. Accessed 7 Nov 2013."},{"key":"153_CR31","doi-asserted-by":"publisher","unstructured":"Hayashi N, Seto C, Kato M, et al. Once-daily simeprevir (TMC435) with peginterferon\/ribavirin for treatment-na\u00efve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol. 2013. doi:10.1007\/s00535-013-0875-1","DOI":"10.1007\/s00535-013-0875-1"},{"key":"153_CR32","doi-asserted-by":"publisher","first-page":"S483","DOI":"10.1016\/S0168-8278(13)61189-7","volume":"58","author":"S Bourgeois","year":"2013","unstructured":"Bourgeois S, Reesink HW, Leempoels J, et al. Combination therapy of TMC647055 with simeprevir (TMC435) in chronic hepatitis C patients. J Hepatol. 2013;58:S483.","journal-title":"J Hepatol."},{"issue":"Suppl. 1","key":"153_CR33","first-page":"857","volume":"46","author":"K Simmen","year":"2007","unstructured":"Simmen K, Lenz O, Lin TI, et al. In vitro activity and preclinical pharmacokinetics of the HCV protease inhibitor, TMC435350. Hepatology. 2007;46(Suppl. 1):857.","journal-title":"Hepatology."},{"key":"153_CR34","unstructured":"Manns MP, Reesink HW, Moreno C, et al. Safety and antiviral activity of TMC435350 in treatment-naive genotype 1 HCV- infected patients [abstract no. LB8]. 59th Annual Meeting of the American Association for the Study of Liver Diseases; 2008 Oct 31\u2013Nov 1; San Francisco (CA); 2008."},{"issue":"3","key":"153_CR35","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1053\/j.gastro.2009.10.033","volume":"138","author":"HW Reesink","year":"2010","unstructured":"Reesink HW, Fanning GC, Farha KA, et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology. 2010;138(3):913\u201321.","journal-title":"Gastroenterology."},{"key":"153_CR36","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3851\/IMP1894","volume":"15","author":"M Manns","year":"2011","unstructured":"Manns M, Reesink H, Berg T, et al. Rapid viral response of once-daily TMC435 plus pegylated interferon\/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Antivir Ther. 2011;15:1021\u201333.","journal-title":"Antivir Ther."},{"key":"153_CR37","doi-asserted-by":"crossref","unstructured":"Marcellin P, Reesink H, Berg T, et al. Antiviral activity and safety of TMC435 combined with peginterferon alpha-2A and ribavirin in patients with genotype 1 hepatitis C infection who failed previous IFN-based therapy [abstract no. 1058]. 44th Annual Meeting of the European Association for the Study of the Liver; 2009 Apr 22\u201326; Copenhagen, Denmark, S385; 2009.","DOI":"10.1016\/S0168-8278(09)61060-6"},{"issue":"3","key":"153_CR38","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jhep.2012.10.028","volume":"58","author":"O Lenz","year":"2013","unstructured":"Lenz O, Vijgen L, Berke JM, et al. Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202). J Hepatol. 2013;58(3):445\u201351.","journal-title":"J Hepatol."},{"issue":"6","key":"153_CR39","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.jhep.2011.12.033","volume":"56","author":"C Moreno","year":"2012","unstructured":"Moreno C, Berg T, Tanwandee T, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol. 2012;56(6):1247\u201353.","journal-title":"J Hepatol."},{"issue":"5","key":"153_CR40","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2012.07.117","volume":"143","author":"O Lenz","year":"2012","unstructured":"Lenz O, De Bruijne J, Vijgen L, et al. Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus-infected patients following TMC435 monotherapy. Gastroenterology. 2012;143(5):1176\u20138.e6.","journal-title":"Gastroenterology"},{"key":"153_CR41","unstructured":"Lenz O, Vijgen L, Lin Tl, et al. Virologic analysis of genotype-1-infected patients treated with once-daily Tmc435 during the optimal protease inhibitor enhancement of response to therapy (Opera)-1 study [abstract no. 812]. 61st Annual Meeting of the American Association for the Study of Liver Diseases; 2010 Oct 30\u2013Nov 3 Boston (MA); 2010."},{"key":"153_CR42","first-page":"A28","volume":"17","author":"O Lenz","year":"2012","unstructured":"Lenz O, Fevery B, Vijgen L, et al. Resistance profile of TMC435 in HCV genotype- 1-infected patients: Virological analyses of the PILLAR and ASPIRE Phase IIb trials. Antivir Ther. 2012;17:A28.","journal-title":"Antivir Ther."},{"key":"153_CR43","unstructured":"Lenz O. Resistance analyses of HCV isolates from patients treated with simeprevir in phase 2b\/3 studies [poster plus abstract no. 1101]. 64th annual meeting of the American Association for the Study of Liver Diseases (AASLD 2013); 2013 November 1\u20135 Washington, DC; 2013."},{"key":"153_CR44","first-page":"S319","volume":"52","author":"V Sekar","year":"2010","unstructured":"Sekar V, Vis P, Lenz O, et al. Pharmacokinetic-pharmacodynamic (pk-pd) analyses of TMC435 in treatment-naive hepatitis C (HCV)-infected patients in the Opera-1 study [poster no. 1075]. J Hepatol. 2010;52:S319\u2013457.","journal-title":"J Hepatol"},{"key":"153_CR45","unstructured":"van \u2018t Klooster GA, Vanwelkenhuysen I, Verloes R, et al. Pharmacokinetics of once-daily regimens of the novel HCV NS3\/4A-protease inhibitor TMC435350, with and without PEGIFN and ribavirin, in HCV-infected individuals [abstract]. 59th Annual Meeting of the American Association for the Study of Liver Diseases (AALSD); 2008 Oct 31\u2013Nov 1; San Francisco (CA); 2008."},{"issue":"Suppl. 1","key":"153_CR46","first-page":"823","volume":"46","author":"R Verloes","year":"2007","unstructured":"Verloes R, Farha KA, van Vliet A, et al. Results of a phase I placebo-controlled trial in healthy volunteers to examine the safety, tolerability and pharmacokinetics of the HCV protease inhibitor TMC435350 after single and repeated dosing. Hepatology. 2007;46(Suppl. 1):823\u20134.","journal-title":"Hepatology."},{"key":"153_CR47","doi-asserted-by":"crossref","unstructured":"van t Klooster GAE, Vanwelkenhuysen I, Hooijmaijers R, et al. Once-daily regimens of the HCV NS3\/4A-protease inhibitor TMC435350 are predicted to provide therapeutic exposure in plasma and liver. 43rd annual meeting of the European Association for the Study of the Liver. 2008.","DOI":"10.1016\/S0168-8278(08)60857-0"},{"key":"153_CR48","doi-asserted-by":"crossref","unstructured":"Reesink H, Verloes R, Farha KA, et al. Safety of the HCV protease inhibitor TMC435350 in healthy volunteers and safety and activity in chronic hepatitis C infected individuals: a phase I study. 43rd annual meeting of the European Association for the Study of the Liver. 2008.","DOI":"10.1016\/S0168-8278(08)60066-5"},{"key":"153_CR49","unstructured":"Janssen. Antiviral Drugs Advisory Committee Meeting Briefing Document Simeprevir (TMC435) Treatment of patients with chronic hepatitis C NDA 205123. October 2013. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AntiviralDrugsAdvisoryCommittee\/UCM371624.pdf. Accessed 11 Nov 2013."},{"key":"153_CR50","doi-asserted-by":"publisher","first-page":"S365","DOI":"10.1016\/S0168-8278(13)60889-2","volume":"58","author":"S Ouwerkerk-Mahadevan","year":"2013","unstructured":"Ouwerkerk-Mahadevan S, Simion A, Spittaels K, et al. Pharmacokinetics of simeprevir (TMC435) in volunteers with moderate or severe hepatic impairment. J Hepatol. 2013;58:S365.","journal-title":"J Hepatol."},{"key":"153_CR51","doi-asserted-by":"crossref","unstructured":"Sekar V, Verloes R, Meyvisch P, et al. Evaluation of metabolic interactions for TMC435 via cytochrome P450 enzymes in healthy volunteers [abstract no. 1076]. 45th Annual Meeting of the European Association for the Study of the Liver; 2010 Apr 14\u201318; Vienna, Austria.","DOI":"10.1016\/S0168-8278(10)61077-X"},{"key":"153_CR52","unstructured":"Ouwerkerk-Mahadevan S, Sekar V, Peeters M. The pharmacokinetic Interactions of HCV protease inhibitor TMC435 with RPV, TDF, EFV, or RAL in healthy volunteers [abstract no. 49]. 19th Conference on Retroviruses and Opportunistic Infections, March 5\u20138, 2012, Seattle (WA); 2012."},{"key":"153_CR53","first-page":"565A","volume":"56","author":"S Ouwerkerk-Mahadevan","year":"2012","unstructured":"Ouwerkerk-Mahadevan S, Beumont M, Spittaels KF, et al. No pharmacokinetic interaction between the investigational HCV protease inhibitor TMC435 and an oral contraceptive containing ethinylestradiol and norethindrone. Hepatology. 2012;56:565A\u20136A.","journal-title":"Hepatology."},{"key":"153_CR54","first-page":"231A","volume":"56","author":"S Ouwerkerk-Mahadevan","year":"2012","unstructured":"Ouwerkerk-Mahadevan S, Simion A, Mortier S, et al. No clinically significant interaction between the investigational HCV protease inhibitor TMC435 and the immunosuppressives cyclosporine and tacrolimus. Hepatology. 2012;56:231A.","journal-title":"Hepatology."},{"key":"153_CR55","doi-asserted-by":"publisher","unstructured":"Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013. doi:10.1002\/hep.26641","DOI":"10.1002\/hep.26641"},{"key":"153_CR56","unstructured":"Janssen Pharmaceuticals I. Efficacy and safety data from phase 2B trials of Janssen\u2019s Simeprevir in hepatitis C patients with advanced fibrosis of the liver presented at annual meeting of the American Association for the Study of Liver Diseases. Media Release; 2012."},{"key":"153_CR57","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/S0168-8278(12)60023-3","volume":"56","author":"O Lenz","year":"2012","unstructured":"Lenz O, Fevery B, Vijgen L, et al. TMC435 in patients infected with HCV genotype 1 who have failed previous pegylated interferon\/ribavirin treatment: virologic analyses of the aspire trial. J Hepatol. 2012;56:S5.","journal-title":"J Hepatol."},{"key":"153_CR58","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S0168-8278(12)60016-6","volume":"56","author":"S Zeuzem","year":"2012","unstructured":"Zeuzem S, Berg T, Gane E, et al. TMC435 in HCV genotype 1 patients who have failed previous pegylated interferon\/ribavirin treatment: final SVR24 results of the aspire trial. J Hepatol. 2012;56:S1\u20132.","journal-title":"J Hepatol."},{"issue":"1","key":"153_CR59","first-page":"187","volume":"6","author":"S Zeuzem","year":"2012","unstructured":"Zeuzem S, Foster G, Fried M, et al. The ASPIRE trial: once-daily TMC435 in treatment-experienced patients with genotype 1 HCV infection who have failed previous PegIFN\/RBV treatment. Hepatol Int. 2012;6(1):187\u20138.","journal-title":"Hepatol Int"},{"key":"153_CR60","doi-asserted-by":"crossref","unstructured":"Zeuzem S, Foster GR, Fried MW, et al. The Aspire Trial: Tmc435 in treatment-experienced patients with genotype-1 Hcv infection who have failed previous Pegifn\/Rbv treatment [abstract no. 1376]. 46th annual meeting of the European Association for the Study of the Liver; 2011 Mar 30\u2013Apr 3; Berlin, Germany; 2011.","DOI":"10.1016\/S0168-8278(11)61378-0"},{"key":"153_CR61","unstructured":"Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology epub 2013 Oct 31. 2013."},{"key":"153_CR62","unstructured":"Jacobson IM, Ghalib RM, Rodriguez-Torres M, et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study [abstract LB-3]. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013); 2013 November 1\u20135; Washington, DC; 2013."},{"key":"153_CR63","unstructured":"Medivir. Results from the COSMOS study with simeprevir and sofosbuvir in cirrhotic and non-cirrhotic HCV genotype 1 patients presented at AASLD. 2013. http:\/\/www.medivir.se\/v5\/en\/uptodate\/pressrelease.cfm. Accessed 21 Nov 2013."},{"key":"153_CR64","unstructured":"Lawitz E, Ghalib R, Rodriguez-Torres M, et al. Suppression of viral load through 4\u00a0weeks post-treatment results of a once-daily regimen of simeprevir\u00a0+\u00a0sofosbuvir with or without ribavirin in hepatitis C virus GT 1 null responders [abstract no. 155LB]. 20th Conference on Retroviruses and Opportunistic Infections; 2013 Mar 3\u20136; Atlanta (GA); 2013."},{"key":"153_CR65","doi-asserted-by":"crossref","first-page":"S374","DOI":"10.1016\/S0016-5085(13)61382-7","volume":"1","author":"E Lawitz","year":"2013","unstructured":"Lawitz E, Ghalib R, Rodriguez-Torres M, et al. SVR4 results of a once daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin (RBV) in HCV GT 1 null responders. Gastroenterology. 2013;1:S374\u20135.","journal-title":"Gastroenterology."},{"key":"153_CR66","unstructured":"Medivir AB. Medivir announces interim results from Cohort 2 of the COSMOS study evaluating simeprevir and sofosbuvir in HCV patients with METAVIR scores F3-F4. 2013. http:\/\/www.medivir.com. Accessed 21 Nov 2013."},{"key":"153_CR67","doi-asserted-by":"crossref","unstructured":"Manns M, Reesink H, Moreno C, et al. OPERA-1 Trial: interim analysis of safety and antiviral activity of TMC435 in treatment-naive genotype 1 HCV patients [abstract no. 11]. 44th Annual Meeting of the European Association for the Study of the Liver; 2009 Apr 22\u201326; Copenhagen, Denmark, S7; 2009.","DOI":"10.1016\/S0168-8278(09)60013-1"},{"key":"153_CR68","unstructured":"Reesink HW, de Bruijne J, Weegink CJ, et al. Antiviral activity and safety of TMC435 combined with pegylated interferon and ribavirin in hepatitis C patients with genotype-1 who had previous exposure to TMC435 [poster no. 1563]. 60th annual meeting of the American Association for the Study of Liver Diseases; 2009 Oct 30\u2013Nov 3; Boston, (MA); 2009."},{"key":"153_CR69","unstructured":"Johnson & Johnson. Primary efficacy and safety findings from four phase 3 Japanese studies of simeprevir administered once daily demonstrate sustained virologic response in genotype 1 chronic hepatitis C adult patients http:\/\/www.investor.jnj.com\/releasedetail.cfm?ReleaseID=769679. Accessed 17 Oct 2013."},{"key":"153_CR70","unstructured":"Medivir AB. Primary efficacy and safety data from four phase III Japanese studies of Simeprevir presented at The Japan Society of Hepatology. Media Release. 2013. http:\/\/news.cision.com\/medivir\/r\/primary-efficacy-and-safety-data-from-four-phase-iii-japanese-studies-of-simeprevir-presented-at-the,c9425114"},{"key":"153_CR71","doi-asserted-by":"crossref","unstructured":"Jacobson IM, Dore GJ, Foster G, et al. Simeprevir (TMC435) with peginterferon\/ribavirin for chronic HCV genotype-1 infection in treatment-naive patients: results from Quest-1, a phase III trial [abstract no. Sa2072]. Digestive Disease Week; 2013 May 18\u201321; Orlando (FL); 2013.","DOI":"10.1016\/S0016-5085(13)61381-5"},{"key":"153_CR72","doi-asserted-by":"publisher","first-page":"S574","DOI":"10.1016\/S0168-8278(13)61424-5","volume":"58","author":"I Jacobson","year":"2013","unstructured":"Jacobson I, Dore GJ, Foster GR, et al. Simeprevir (TMC435) with peginterferon\/ribavirin for chronic HCV genotype-1 infection in treatment-naive patients: results from quest-1, a phase III trial. J Hepatol. 2013;58:S574.","journal-title":"J Hepatol."},{"key":"153_CR73","doi-asserted-by":"publisher","first-page":"S568","DOI":"10.1016\/S0168-8278(13)61412-9","volume":"58","author":"M Manns","year":"2013","unstructured":"Manns M, Marcellin P. Fred Poordad FP, et al. Simeprevir (TMC435) with peginterferon\/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from Quest-2, a phase III trial. J Hepatol. 2013;58:S568.","journal-title":"J Hepatol."},{"key":"153_CR74","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1016\/S0016-5085(13)60541-7","volume":"1","author":"F Poordad","year":"2013","unstructured":"Poordad F, Manns MP, Marcellin P, et al. Simeprevir (TMC435) with peginterferon\/ribavirin for treatment of chronic hcv genotype-1 infection in treatment-naive patients: results from Quest-2, a phase III trial. Gastroenterology. 2013;1:S151.","journal-title":"Gastroenterology."},{"key":"153_CR75","unstructured":"Jacobson I. Simeprevir (TMC435) with peginterferon\/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naive patients: efficacy in difficult-to-treat patient sub-populations in the QUEST 1 and 2 phase III trials [abstract no. 1122]. 64th annual meeting of the American Association for the Study of Liver Diseases (AASLD 2013); 2013 November 1\u20135; Washington, DC; 2013."},{"key":"153_CR76","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1016\/S0016-5085(13)60542-9","volume":"1","author":"E Lawitz","year":"2013","unstructured":"Lawitz E, Forns X, Zeuzem S, et al. Simeprevir (TMC435) with peginterferon\/ribavirin for treatment of chronic hcv genotype 1 infection in patients who relapsed after previous interferon-based therapy: results from promise, a phase III trial. Gastroenterology. 2013;1:S151.","journal-title":"Gastroenterology."},{"key":"153_CR77","unstructured":"Forns X. Simeprevir (TMC435) with peg-interferon alpha-2a\/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: efficacy and safety in patient sub-populations in the PROMISE phase III trial [poster and abstract no. 1092]. 64th annual meeting of the American Association for the Study of Liver Diseases (AASLD 2013); 2013 November 1\u20135; Washington, DC; 2013."},{"key":"153_CR78","unstructured":"Scott J. Adding simeprevir to peginterferon\/ribavirin for HCV shortens time with patient-reported symptoms and impairment in quality of life: Results from the simeprevir Phase III QUEST 1, QUEST 2 and PROMISE studies [poster and abstract no. 1116] 64th annual meeting of the American Association for the Study of Liver Diseases (AASLD 2013); 2013 November 1\u20135; Washington, DC; 2013."},{"key":"153_CR79","unstructured":"Nakajima T. Comparison of simeprevir plus peginterferon\/ribavirin and telaprevir plus peginterferon\/ribavirin for patients with HCV genotype 1 [abstract no. 1930]. 64th annual meeting of the American Association for the Study of Liver Diseases (AASLD 2013); 2013 November 1\u20135; Washington, DC; 2013."},{"key":"153_CR80","doi-asserted-by":"publisher","first-page":"S458","DOI":"10.1016\/S0168-8278(12)61171-4","volume":"56","author":"A Simion","year":"2012","unstructured":"Simion A, Janssens L, Peeters M, et al. Absence of photosensitivity potential of TMC435 in healthy volunteers. J Hepatol. 2012;56:S458.","journal-title":"J Hepatol."},{"key":"153_CR81","unstructured":"ClinicalTrials.gov. TMC435 Clinical studies. http:\/\/clinicaltrials.gov\/ct2\/results?term=TMC435&Search=Search. Accessed 7 Nov 2013."},{"key":"153_CR82","unstructured":"ClinicalTrials.gov. A study of TMC435 plus pegylated interferon alfa-2a and ribavirin in participants with chronic HCV infection (NCT01846832). http:\/\/clinicaltrials.gov\/show\/NCT01846832. Accessed 7 Nov 2013."},{"key":"153_CR83","unstructured":"ClinicalTrials.gov. IDX719 in combination with simeprevir and ribavirin for 12\u00a0weeks in subjects with chronic hepatitis C infection (NCT01852604). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01852604?term=NCT01852604&rank=1. Accessed 7 Nov 2013."},{"key":"153_CR84","unstructured":"ClinicalTrials.gov. A study of pharmacokinetics, efficacy, safety, tolerability, of the combination of simeprevir (TMC435), daclatasvir (BMS-790052), and ribavirin (RBV) in patients with recurrent chronic hepatitis C genotype 1b infection after orthotopic liver transplantation (NCT01938625) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01938625?term=NCT01938625&rank=1. Accessed 7 Nov 2013."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0153-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-013-0153-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0153-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0153-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T16:32:59Z","timestamp":1659112379000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-013-0153-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,30]]},"references-count":84,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["153"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0153-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,30]]},"assertion":[{"value":"30 November 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}